Dr. DiNardo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161Fax+1 713-792-2861- Is this information wrong?
Education & Training
- University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2009 - 2012
- University of Pennsylvania Health SystemResidency, Internal Medicine, 2006 - 2009
- University of Michigan Medical SchoolClass of 2006
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2012 - 2025
- WA State Medical License 2022 - 2025
- GA State Medical License 2022 - 2024
- AZ State Medical License 2022 - 2024
- MS State Medical License 2022 - 2024
- TN State Medical License 2022 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Mar 01
- Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome Start of enrollment: 2017 Nov 15
- Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome Start of enrollment: 2018 Jan 17
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsLong-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.Keith W Pratz, Brian A Jonas, Vinod Pullarkat, Michael J Thirman, Jacqueline S Garcia, Hartmut Döhner, Christian Récher, Walter Fiedler, Kazuhito Yamamoto, Jianxiang W...> ;American Journal of Hematology. 2024 Apr 1
- Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.Alex Bataller, Courtney D DiNardo, Alexandre Bazinet, Naval G Daver, Abhishek Maiti, Gautam Borthakur, Nicholas Short, Koji Sasaki, Elias J Jabbour, Ghayas C Issa, Nav...> ;American Journal of Hematology. 2024 Apr 1
- Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm,...Alexandre Bazinet, Hagop Kantarjian, Alex Bataller, Naveen Pemmaraju, Gautam Borthakur, Kelly Chien, Yesid Alvarado, Prithviraj Bose, Elias Jabbour, Musa Yilmaz, Court...> ;The Lancet. Haematology. 2024 Apr 1
- Join now to see all
Journal Articles
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaCourtney D Dinardo, Brian A Jonas, Jacqueline S Garcia, Anthony Letai, Wan-Jen Hong, Keith W Pratz, The New England Journal of Medicine
- Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid LeukemiaBrian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood
- Mutational Landscape of myelodysplastic/myeloproliferative Neoplasm – Unclassifiable (MDS/MPN-U)Aziz Nazha, Rami S Komrokji, Andrew Sochacki, Mikkael A Sekeres, Prithviraj Bose, Courtney D DiNardo, Hagop M Kantarjian, Srdan Verstovsek, Sanam Loghavi, Jaroslaw P M..., Blood
- Join now to see all
Abstracts/Posters
- High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosid...Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDSCourtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Expression Profiling of mRNA By Next Generation Sequencing and the Development of Algorithm for Predicting Response in Acute Myeloid LeukemiaCourtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Therapy of Acute Myeloid Leukemia: Adapting to Change61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).2019 ASCO Annual Meeting - 6/1/2019
- Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant M...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Authored Content
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid MalignanciesOctober 2017
- The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017
- Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 Days (SGI5), 10 Days (SGI10), 5 Days + Idarubicin (SGI5 + Ida), and 5 Days + Cladribine (SGI5 + Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)–a Bayesian DesignOctober 2017
- A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017
- Join now to see all
Press Mentions
- MD Anderson Research Highlights for May 10, 2023May 10th, 2023
- MD Anderson Research Highlights for February 1, 2023February 1st, 2023
- Intermediate Induction Dose Sufficient in AMLJanuary 19th, 2023
- Join now to see all
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: